期刊文献+

琥珀酸索利那新治疗女性膀胱过度活动症体会 被引量:3

下载PDF
导出
摘要 探讨琥珀酸索利那新对女性膀胱过度活动症的治疗效果。分别应用琥珀酸索利那新(54例)和酒石酸托特罗定(55例)治疗女性膀胱过度活动症患者,收集临床资料,评价两种药物在疗效方面的差异,并结合文献复习。109例患者治疗10~12周后,获得随访104例,其中琥珀酸索利那新组51例,有效39例,总有效率为76.5%,其中症状完全消失24例(61.50%),明显好转7例(17.9%),8例无效(20.5%);酒石酸托特罗定52例,有效35例,总有效率67.3%,其中症状完全消失17例(48.6%),明显好转7例(20.0%),11例无效(31.4%);随访时间3~12个月,平均6.5月;两组比较,差别无显著意义(P〈0.05)。服药期间无明显不适,仅少数患者出现轻微口干和排尿费力等。琥珀酸索利那新和酒石酸托特罗定都是治疗女性膀胱过度活动症有效的药物而前者疗效优于后者。
出处 《甘肃科技》 2015年第3期145-146,126,共3页 Gansu Science and Technology
  • 相关文献

参考文献6

  • 1Haylen BT, de Ridder D, Freeman RM, et al. An Intema tional Urogyneoological Association (IUGA)/Interaational Continence Socitty (ICS) joint report on the terminology for female pelvic floor dysfunction [J]. Neurourol Uro dyn, 2010(29)4-6. 被引量:1
  • 2Fitzgerald MP,Link CL,Litman HJ,et al.Beyond the lower urinary tract:The association of urologic and sexual symptoms with common illnesses[J].Eur Urol, 2007 (52) : 407-501. 被引量:1
  • 3Kupelian V,M cVary KT,Kaplan SA,et al.Association of lower urinary tract symptoms and the metabolic syndrome: Restdts from the Boston Area Community Health Survey [J]JUrol,2009,182:616-619. 被引量:1
  • 4金锡御,宋波,杨勇,张小东,廖利民.膀胱过度活动症临床指导原则[J].中华泌尿外科杂志,2002,23(5):311-313. 被引量:138
  • 5Hashim Hashim.Paul Abrams.Drug treatment of overactive bladder[J].Drugs, 2004,64(15) : 1-643. 被引量:1
  • 6吴士良,肖云翔,段继宏,丁强,孙颖浩,黄翼然,宋波,蔡松良,那彦群.索利那新治疗尿急及急迫性尿失禁的有效性和安全性分析[J].中华泌尿外科杂志,2009,30(9):630-634. 被引量:71

二级参考文献16

  • 1Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function, report from the standardisaton subcommittee of the International Continence Society. Neurourol Urodyn, 2002, 21: 167-178. 被引量:1
  • 2Rovner ES, Wein AJ. Incidence and prevalence of overactive bladder. Curr Urol Rep, 2002, 3:434- 438. 被引量:1
  • 3Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int, 2006, 97: 96-100. 被引量:1
  • 4Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int, 2007, 100: 987-1006. 被引量:1
  • 5Ikeda K, Kobayashi S, Suzuki M, et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. N-S Arch Pharmacol, 2002, 366: 97-103. 被引量:1
  • 6Ohtake A, Ukai M, Hatanaka T, et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmaeol, 2004, 492:243- 250. 被引量:1
  • 7Kobayashi S, Ikeda K, Miyata K. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. Life Sci, 2004, 74: 843-853. 被引量:1
  • 8Smulders RA, Krauwinkel WJ, Swart PJ, et al. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol, 2004, 44:1023- 1033. 被引量:1
  • 9Chapple CR, Arano P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int, 2004, 93: 71-77. 被引量:1
  • 10宋波,杨勇,廖利民.膀胱过度活动症诊断治疗指南∥那彦群.中国泌尿外科疾病诊断治疗指南.北京:人民卫生出版社,2007:330. 被引量:2

共引文献205

同被引文献21

  • 1陈敏,杨军,鞠文,曾甫清,肖传国.不同生理阶段女性下尿路感染治疗的研究[J].临床泌尿外科杂志,2004,19(11):649-651. 被引量:6
  • 2ABRAMS P,CARDOZO L,FALL M,et al.The standardisation of terminology of lower urinary tract function:report from the Standardisation Sub-committee of the International Continence Society[J].Neurourol Urodyn,2002,21(2):167-178. 被引量:1
  • 3ABRAMS P,ARTIBANI W,CARDOZO L,et al.Reviewing the ICS 2002 terminology report:the ongoing debate[J].Neurourol Urodyn,2009,28(4):287. 被引量:1
  • 4那彦群,叶章群,孙颖浩,等.2014版中国泌尿外科疾病诊断治疗指南·膀胱过度活动症诊治指南[M].北京:人民卫生出版社,2014:452-453. 被引量:1
  • 5CHAPPLE CR,RECHBERGER T,AL-SHUKRI S,et al.Randomized,double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder[J].BJU Int,2004,93(3):303-310. 被引量:1
  • 6CHAPPLE CR,MARTINEZ-GARCIA R,SELVAGGI L,et al.A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome:results of the STAR trial[J].Eur Urol,2005,48(3):464-470. 被引量:1
  • 7KOBELT G,JONSSON L,MATTIASSON A.Cost-effectiveness of newtreatments for overactive bladder:the example of tolterodine,a new muscarinic agent:a Markov model[J].Neurourol Urodyn,1998,17(6):599-611. 被引量:1
  • 8JOHANNESSON M,O'CONOR RM,KOBELT-NGUYEN G,et al.Willingness to pay for reduced incontinence symptoms[J].Br J Urol,1997,80(4):557-662. 被引量:1
  • 9MILSOM I,ABRAMS P,CARDOZO L,et al.How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study[J].BJU Int,2001,87(9):760-766. 被引量:1
  • 10COYNE KS,PAYNE C,BHATTACHARYYA SK,et al.The impact ofurinary urgency and frequency on health-related qualityof life in overactive bladder:results from a national communitysurvey[J].Value Health,2004,7(4):455-463. 被引量:1

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部